Optimum population-level use of artemisinin combination therapies: a modelling study

[1]  R. Maude,et al.  Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker , 2015, The Lancet. Infectious diseases.

[2]  Baldur P Magnusson,et al.  Spiroindolone KAE609 for falciparum and vivax malaria. , 2014, The New England journal of medicine.

[3]  D. Kwiatkowski,et al.  Spread of artemisinin resistance in Plasmodium falciparum malaria. , 2014, The New England journal of medicine.

[4]  B. Genton,et al.  A molecular marker of artemisinin-resistant Plasmodium falciparum malaria , 2013, Nature.

[5]  Prashant Yadav,et al.  Impact of treatment heterogeneity on drug resistance and supply chain costs☆ , 2013, Socio-economic planning sciences.

[6]  J. Le bras,et al.  Longitudinal study assessing the return of chloroquine susceptibility of Plasmodium falciparum in isolates from travellers returning from West and Central Africa, 2000–2011 , 2013, Malaria Journal.

[7]  T. Antão,et al.  Policy options for deploying anti-malarial drugs in endemic countries: a population genetics approach , 2012, Malaria Journal.

[8]  C. Dolecek,et al.  In vivo susceptibility of Plasmodium falciparum to artesunate in Binh Phuoc Province, Vietnam , 2012, Malaria Journal.

[9]  A. Nzila,et al.  Update on the in vivo tolerance and in vitro reduced susceptibility to the antimalarial lumefantrine. , 2012, The Journal of antimicrobial chemotherapy.

[10]  A. Surya,et al.  New treatment policy of malaria as a part of malaria control program in Indonesia. , 2012, Acta medica Indonesiana.

[11]  Paul N Newton,et al.  Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa. , 2012, The Lancet. Infectious diseases.

[12]  F. Nosten,et al.  Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study , 2012, The Lancet.

[13]  F. Nosten,et al.  pfmdr1 Amplification Is Related to Increased Plasmodium falciparum In Vitro Sensitivity to the Bisquinoline Piperaquine , 2012, Antimicrobial Agents and Chemotherapy.

[14]  T. Antão,et al.  Environmental, pharmacological and genetic influences on the spread of drug-resistant malaria , 2011, Proceedings of the Royal Society B: Biological Sciences.

[15]  S. Khoo,et al.  Artemether-Lumefantrine Combination Therapy for Treatment of Uncomplicated Malaria: The Potential for Complex Interactions with Antiretroviral Drugs in HIV-Infected Individuals , 2011, Malaria research and treatment.

[16]  R. Snow,et al.  Shrinking the malaria map: progress and prospects , 2010, Lancet.

[17]  Rajendra Maharaj,et al.  Operational strategies to achieve and maintain malaria elimination , 2010, The Lancet.

[18]  Elizabeth Ashley,et al.  Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial , 2010, The Lancet. Infectious diseases.

[19]  David L. Smith,et al.  Prospective strategies to delay the evolution of anti-malarial drug resistance: weighing the uncertainty , 2010, Malaria Journal.

[20]  R. Maude,et al.  Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance , 2009, Malaria Journal.

[21]  P. Grewal,et al.  Cost is killing patients: subsidising effective antimalarials , 2009, The Lancet.

[22]  Justin M. Cohen,et al.  Piloting the Global Subsidy: The Impact of Subsidized Artemisinin-Based Combination Therapies Distributed through Private Drug Shops in Rural Tanzania , 2009, PloS one.

[23]  J. Simpson,et al.  Population pharmacokinetics of artesunate and amodiaquine in African children , 2009, Malaria Journal.

[24]  K. Silamut,et al.  Artemisinin resistance in Plasmodium falciparum malaria. , 2009, The New England journal of medicine.

[25]  A. Nzila,et al.  Chloroquine resistance before and after its withdrawal in Kenya , 2009, Malaria Journal.

[26]  Z. Premji,et al.  In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa. , 2009, The Journal of infectious diseases.

[27]  Richard J Maude,et al.  The last man standing is the most resistant: eliminating artemisinin-resistant malaria in Cambodia , 2009, Malaria Journal.

[28]  David L. Smith,et al.  Benefits of using multiple first-line therapies against malaria , 2008, Proceedings of the National Academy of Sciences.

[29]  N. White,et al.  Qinghaosu (Artemisinin): The Price of Success , 2008, Science.

[30]  K. Barnes,et al.  Antimalarial dosing regimens and drug resistance. , 2008, Trends in parasitology.

[31]  I. Kleinschmidt,et al.  Differential effect of regional drug pressure on dihydrofolate reductase and dihydropteroate synthetase mutations in southern Mozambique. , 2008, The American journal of tropical medicine and hygiene.

[32]  E. Lesaffre,et al.  Assessment of the relative advantage of various artesunate-based combination therapies by a multi-treatment Bayesian random-effects meta-analysis. , 2007, The American journal of tropical medicine and hygiene.

[33]  R. Snow,et al.  The challenges of changing national malaria drug policy to artemisinin-based combinations in Kenya , 2007, Malaria Journal.

[34]  Georgina S. Humphreys,et al.  Amodiaquine and Artemether-Lumefantrine Select Distinct Alleles of the Plasmodium falciparum mdr1 Gene in Tanzanian Children Treated for Uncomplicated Malaria , 2006, Antimicrobial Agents and Chemotherapy.

[35]  T. Taylor,et al.  Return of chloroquine antimalarial efficacy in Malawi. , 2006, The New England journal of medicine.

[36]  N. Day,et al.  Pitfalls in Estimating Piperaquine Elimination , 2005, Antimicrobial Agents and Chemotherapy.

[37]  Carl T. Bergstrom,et al.  Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitals. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[38]  J. Kublin,et al.  Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. , 2003, The Journal of infectious diseases.

[39]  Gardner M. Brown,et al.  Economics of Antibiotic Resistance: A Theory of Optimal Use , 2001 .

[40]  T. Q. Toan,et al.  Resistance of Plasmodium falciparum to antimalarial drugs in a highly endemic area of southern Viet Nam: a study in vivo and in vitro. , 2001, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[41]  U. d’Alessandro,et al.  Modelling a predictable disaster: the rise and spread of drug-resistantmalaria. , 2000, Parasitology today.

[42]  S Bonhoeffer,et al.  Evaluating treatment protocols to prevent antibiotic resistance. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[43]  I. Hastings,et al.  A model for the origins and spread of drug-resistant malaria , 1997, Parasitology.

[44]  R. Levins.  Evolution in Changing Environments , 1968 .

[45]  Organización Mundial de la Salud.  Guidelines for the treatment of malaria , 2010 .

[46]  S. Bonhoeffer.  Adaptive Dynamics of Infectious Diseases: Managing Antibiotic Resistance: What Models Tell Us? , 2002 .